Haemonetics price target lowered to $105 from $115 at Raymond James

Raymond James lowered the firm’s price target on Haemonetics (HAE) to $105 from $115 and keeps a Strong Buy rating on the shares. The Q4 print was in line on revenues and slightly ahead on EPS due to below-the-line dynamics, the analyst tells investors in a research note. The guidance for fiscal 2026 is in line to better than hopes even net of a tariff headwind and could still prove conservative, the analyst tells investors in a research note.